Search Results for: dronedarone

2011 in Review: Rivaroxaban, Sapien, Mark Midei, Conflicts of Interest, and Much More

Here’s a completely personal review of the past year in cardiology. Please write a comment if you strongly agree, disagree, or think something is missing. Drug of the Year: Rivaroxaban (Xarelto)– Despite a highly negative review from FDA reviewers, rivaroxaban gained FDA approval for the coveted stroke prevention in AF indication. The drug was approved…

Click here to continue reading…

Industry & Medicine: It’s Complicated

Some people think industry exerts a uniformly negative force on medicine, or at least that’s the only aspect they focus on when they write or talk about the issue. Others focus exclusively on the beneficial effects of industry, and exhibit amnesia in their failure to recall the numerous instances in recent years in which the…

Click here to continue reading…

Guest Post: Multaq’s Off Again, On Again, Then Off Again Ride

CardioBrief welcomes this guest post, reprinted with permission, from Dr. Westby Fisher, an electrophysiologist practicing at NorthShore University HealthSystem in Evanston, Illinois, and a Clinical Associate Professor of Medicine at University of Chicago’s Pritzker School of Medicine. This piece originally appeared on his blog, Dr. Wes. Today was another tough day for Sanofi’s dronedarone antiarrhythmic…

Click here to continue reading…

Study Estimates That AF Adds $26 Billion to Yearly US Healthcare Costs

Atrial fibrillation adds $26 billion to the nation’s healthcare bill, according to a study published in  Circulation: Cardiovascular Quality and Outcomes. Michael Kim and colleagues compared insurance claims for one year from 89,066 AF patients to a group of controls matched for gender, age, and other medical conditions and found that AF results in a…

Click here to continue reading…

AF Guidelines Updated to Incorporate Dabigatran

Less than two months after the publication of the 2010 updated atrial fibrillation (AF) guidelines, the AHA, the ACC, and the HRS have released a new focused update incorporating recommendations and a discussion concerning the direct thrombin inhibitor dabigatran, which gains a Class I recommendation: Class I: Dabigatran is useful as an alternative to warfarin…

Click here to continue reading…

Sanofi-Aventis Provides More Details About Multaq Letter

A Sanofi-Aventis spokesperson has confirmed CardioBrief’s story yesterday and has provided further details and clarifications about the Dear Doctor letter. Here is the Sanofi statement:…

Click here to continue reading…

New Safety Questions Raised About Multaq

The Institute for Safe Medication Practices has identified a potential drug safety signal for dronedarone (Multaq, Sanofi-Aventis). The potential problem is outlined in QuarterWatch: 2010 Quarter 1, a publication of the ISMP that monitors FDA MedWatch reports, and was written about on the Pharmalot blog. The report concludes: Evidence is accumulating that the risks of the…

Click here to continue reading…

Some Remaining Questions About Dabigatran

Yesterday’s approval of dabigatran (Pradaxa) has been long awaited in the cardiology community. Although just about everyone agrees that a good alternative to warfarin is highly desirable, there are many remaining questions about the drug as it prepares to enter the marketplace. Here are a few questions raised by electrophysiologist John Mandrola on his blog:…

Click here to continue reading…

The rise of the ESC: is the ESC anti-American or pro-industry?

A prominent US cardiologist remarked to me in Stockholm that he was disturbed by the “anti-American” tone of some remarks made at the opening session of the ESC. I’m not entirely sure to what he was referring because I make a point of skipping official ceremonies, but I’m certain that at least part of his…

Click here to continue reading…

A missing piece of the Multaq puzzle finally appears: DIONYSOS published to little fanfare

The Greek god Dionysos demanded a great deal of attention. When King Pentheus refused to acknowledge the divinity of Dionysos, the god exacted a terrible and bloody revenge, as recounted in the Bacchae, one of the great tragedies of all time. But the new Dionysos is far less demanding. You might even say he’s shy….

Click here to continue reading…

Can we trust ATHENA?

I’ve written extensively on CardioBrief about Sanofi’s promotion of Multaq (dronedarone). John Fauber, a reporter for the Journal Sentinel in Milwaukee, tackles the topic from an important perspective that often gets ignored or neglected. He focuses on ATHENA, the drug’s pivotal trial, and notes that all the trial authors had financial ties to Sanofi. Further,…

Click here to continue reading…

Even more questions about Multaq and Prystowsky, alas

I’m feeling a bit like Al Pacino in Godfather III: every time I think I’m out of the Multaq story I get pulled back in. A sharp observer forwarded an article posted online in the Journal of Cardiovascular Electrophysiology: “The Impact of New and Emerging Clinical Data on Treatment Strategies for Atrial Fibrillation.” First author:…

Click here to continue reading…

More pieces of the Multaq puzzle

I don’t want to keep harping on Multaq (see the bottom of this post for links to recent stories), but then I keep running across promotions for so-called educational programs that practically beg to be scrutinized. Earlier today I received an email from theheart.org CME Center. At the top of the message was this featured…

Click here to continue reading…

More Multaq: Prystowsky whack-a-mole, ACC responds, Sanofi overtures to EPs

In response to yesterday’s posting about several problems involving a supposedly independent ACC/HRS website (AFibProfessional.org) supported by Sanofi-Aventis, the manufacturer of Multaq (dronedarone), several new events have transpired: Prystowsky Whack-a-Mole– The Eric Prystowsky lecture has been removed from AFibProfessional.org. An ACC spokesperson told CardioBrief that the ACC, in conjunction with its partner, HRS,  was “taking some immediate…

Click here to continue reading…

Pieces of a puzzle: Multaq, Sanofi, ACC, HRS, Prystowsky, AF Guidelines

CardioBrief today dispenses with its usual format. Our post today is a puzzle. Here are the various pieces of the puzzle: Puzzle Piece 1: The commercial prospects of Multaq (dronedarone) appear increasingly cloudy, according to a news report by Jim Edwards on bnet.com. Wall Street estimates for the drug, which some had thought might reach € 3…

Click here to continue reading…

AHRQ gives mixed review to RF catheter ablation for AF

Radiofrequency catheter ablation is increasingly being used to treat atrial fibrillation, but there is little known about its long-term effects, according to a new comparative effectiveness study from the Agency for Healthcare Research and Quality (AHRQ). The study finds good evidence that RF ablation helps keep the heart in sinus rhythm up to one year,…

Click here to continue reading…